THERAPY OF ENDOCRINE DISEASE: Novel protection and treatment strategies for chemotherapy-associated ovarian damage

Eur J Endocrinol. 2021 May;184(5):R177-R192. doi: 10.1530/EJE-20-1178.

Abstract

Fertility and ovarian protection against chemotherapy-associated ovarian damage has formed a new field called oncofertility, which is driven by the pursuit of fertility protection as well as good life quality for numerous female cancer survivors. However, the choice of fertility and ovarian protection method is a difficult problem during chemotherapy and there is no uniform guideline at present. To alleviate ovarian toxicity caused by anticancer drugs, effective methods combined with an individualized treatment plan that integrates an optimal strategy for preserving and restoring reproductive function should be offered from well-established to experimental stages before, during, and after chemotherapy. Although embryo, oocyte, and ovarian tissue cryopreservation are the major methods that have been proven effective and feasible for fertility protection, they are also subject to many limitations. Therefore, this paper mainly discusses the future potential methods and corresponding mechanisms for fertility protection in chemotherapy-associated ovarian damage.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Female
  • Fertility Preservation / methods*
  • Fertility Preservation / trends
  • Humans
  • Infertility, Female / chemically induced*
  • Infertility, Female / prevention & control*
  • Neoplasms / drug therapy
  • Ovarian Reserve / drug effects
  • Ovary / drug effects
  • Ovary / physiology
  • Primary Ovarian Insufficiency / chemically induced
  • Primary Ovarian Insufficiency / prevention & control
  • Primary Ovarian Insufficiency / therapy

Substances

  • Antineoplastic Agents